Skip to main content
Home > The Daily Extra > Company News

Chronological Index of BioCentury Extra, The Daily News: Company News

BioCentury Extra, The Daily News Current Issue
  • COMPANY NEWS: Bayer submits Japanese application for riociguat

    Bayer AG (Xetra:BAYN) submitted a regulatory application in Japan for riociguat to treat chronic thromboembolic pulmonary hypertension (CTEPH). The oral soluble guanylyl cyclase (sGC) stimulator is under Priority Review…

    Published on 5/17/2013
  • COMPANY NEWS: G-BA rebuffs Pixuvri, Trajenta for second indication

    Germany's Federal Joint Committee (G-BA) issued a final benefit assessment rebuffing diabetes drug Trajenta linagliptin from Boehringer Ingelheim GmbH (Ingelheim, Germany) as add-on therapy to insulin with or without …

    Published on 5/17/2013
  • COMPANY NEWS: TaiGen submits nemonoxacin applications in Taiwan, China

    TaiGen Biotechnology Co. Ltd. (Taipei, Taiwan) submitted a pair of NDAs in Taiwan and China for oral nemonoxacin to treat community-acquired pneumonia (CAP). The company, which said these are the first applications …

    Published on 5/17/2013
  • COMPANY NEWS: Aegerion gains on Juxtapid update

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) jumped $14.73 (31%) to $61.70 on Thursday after the company said late Wednesday that the "launch metrics" for Juxtapid lomitapide are ahead of the company's internal plan and …

    Published on 5/16/2013
  • COMPANY NEWS: Evotec, Harvard in antibacterials deal

    Evotec AG (Xetra:EVT) and Harvard University partnered to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. Harvard will contribute research on proprietary assays, chemical starting points …

    Published on 5/16/2013
  • COMPANY NEWS: FDA to discuss QRxPharma's MoxDuo

    FDA's Anesthetic and Analgesic Drug Products Advisory Committee will meet on July 17 to discuss an NDA from QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY) for MoxDuo IR morphine/oxycodone to treat moderate to severe acute pain. …

    Published on 5/16/2013
  • COMPANY NEWS: G-BA says Adcetris has 'unquantifiable' additional benefit

    Germany's Federal Joint Committee (G-BA) said in a final assessment that lymphoma drug Adcetris brentuximab vedotin from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) has an "unquantifiable" degree of additional benefit. …

    Published on 5/16/2013
  • COMPANY NEWS: IBM, UCB in big data deal for epilepsy

    IBM Corp. (NYSE:IBM) and UCB Group (Euronext:UCB) partnered to develop a point-of-care analytics system to predict the probability of success of epilepsy treatments to inform treatment decisions. The partners said they …

    Published on 5/16/2013
  • COMPANY NEWS: Intra-Cellular appoints Rawlins to board

    Neurology company Intra-Cellular Therapies Inc. (New York, N.Y.) appointed Sir Michael Rawlins, former chairman of the U.K.'s NICE, as a director. Rawlins' term ended on March 31, 2013; he had been chairman since the …

    Published on 5/16/2013
  • COMPANY NEWS: Roche, QB3 partner to launch startups

    Roche (SIX:ROG; OTCQX:RHHBY) partnered with the California Institute for Quantitative Biosciences (QB3) to launch the Collaborative Startups program to identify, fund and support early life science startups in the San …

    Published on 5/16/2013
  • COMPANY NEWS: ABLE questions Indian approval of Cipla biosimilar

    India's Association of Biotechnology Led Enterprises sent a letter to the Drug Controller General of India (DCGI) asking whether the approval of biosimilar Etacept from Cipla Ltd. (Mumbai, India) was based on India's …

    Published on 5/15/2013
  • COMPANY NEWS: Bayer, QB3 partner on life science startups

    The Bayer Healthcare LLC subsidiary of Bayer AG (Xetra:BAYN) partnered with the California Institute for Quantitative Biosciences (QB3) under a three-year deal to evaluate and support life science startups from QB3. The…

    Published on 5/15/2013
  • COMPANY NEWS: FDA approves radium-223 from Bayer, Algeta

    FDA approved an NDA from Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is indicated for men whose cancer…

    Published on 5/15/2013
  • COMPANY NEWS: Novartis loses bid to stop German gliptin review

    A German court on Wednesday dismissed a suit from Novartis AG (NYSE:NVS; SIX:NOVN) seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. …

    Published on 5/15/2013
  • COMPANY NEWS: Alvine grants AbbVie option for celiac compound

    Alvine Pharmaceuticals Inc. (San Carlos, Calif.) granted AbbVie Inc. (NYSE:ABBV) an exclusive option to acquire the company or its ALV003, which is in Phase II testing to treat celiac disease, under undisclosed terms. …

    Published on 5/14/2013
  • COMPANY NEWS: FDA expands Tarceva label, approves companion diagnostic

    FDA approved an sNDA from Astellas Pharma Inc. (Tokyo:4503) on Tuesday to expand the label for Tarceva erlotinib and also approved the cobas EGFR Mutation Test from partner Roche (SIX:ROG; OTCQX:RHHBY) as a companion …

    Published on 5/14/2013
  • COMPANY NEWS: FDA to review sBLA to expand Adcetris label

    Seattle Genetics Inc. (NASDAQ:SGEN) said FDA accepted for review an sBLA to expand the label of Adcetris brentuximab vedotin to include retreatment and an extended duration of treatment beyond 16 cycles in relapsed …

    Published on 5/14/2013
  • COMPANY NEWS: AbbVie CSO retiring

    AbbVie Inc. (NYSE:ABBV) disclosed in an SEC filing that SVP and CSO John Leonard will retire in the "next few months." AbbVie said Leonard will be involved in the transition process for naming his successor. Leonard was…

    Published on 5/13/2013
  • COMPANY NEWS: Cempra grants Toyama Japanese rights to solithromycin

    Cempra Inc. (NASDAQ:CEMP) granted Toyama Chemical Co. Ltd. exclusive rights to develop and commercialize solithromycin in Japan. The fluoroketolide/macrolide antibiotic is in Phase III testing to treat moderate to …

    Published on 5/13/2013
  • COMPANY NEWS: FDA to review Biogen Idec's rFVIIIFc for hemophilia A

    Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA for Eloctate rFVIIIFc to treat hemophilia A. The company submitted the application in March; a standard review would place the PDUFA date in March 2014, …

    Published on 5/13/2013
  • COMPANY NEWS: Priority Review for simeprevir from J&J, Medivir

    FDA accepted and granted Priority Review to an NDA from the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) for simeprevir to treat HCV genotype 1 infection in adult patients with compensated …

    Published on 5/13/2013
  • COMPANY NEWS: Vectura forms Chinese newco for asthma, COPD devices

    Vectura Group plc (LSE:VEC) partnered with Tianjin KingYork Group Co. Ltd. and private equity investor Zendex Bio Strategy to form a JV -- Tianjin Kinnovata Pharmaceutical Co. Ltd. -- to develop and commercialize …

    Published on 5/13/2013
  • COMPANY NEWS: Actavis, Warner Chilcott in merger talks

    Shares of generics company Actavis Inc. (NYSE:ACT) and specialty pharma Warner Chilcott plc (NASDAQ:WCRX) jumped on Friday after the companies disclosed before market close they are in "early stage" discussions to merge…

    Published on 5/10/2013
  • COMPANY NEWS: Durect, Pain fall on Pfizer Remoxy update

    Shares of Durect Corp. (NASDAQ:DRRX) and Pain Therapeutics Inc. (NASDAQ:PTIE) slid on Friday after partner Pfizer Inc. (NYSE:PFE) disclosed in an SEC filing that if it "elect[s] to continue development" of Remoxy …

    Published on 5/10/2013
  • COMPANY NEWS: FDA denies Endo petition

    FDA denied a 2012 Citizen Petition from Endo Health Solutions Inc. (NASDAQ:ENDP) asking the agency to determine that the original formulation of the company's pain drug Opana ER oxymorphone had been withdrawn due to …

    Published on 5/10/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.